There is no scientific evidence that people take advantage of reboxetine on depression in May. However, no clinical trials do not close out the use of bupropion, and mirtazapine XL: Both drugs can relieve symptoms. That is the conclusion of the final report of the Institute for Quality and Efficiency of Health Care (IQWiG) Published November 24, 2009th
The final evaluation of reboxetine and mirtazapine was only possible for manufacturer publishes the data that were previously hidden. This case demonstrates again the need for binding rules requiring that all trials be registered at the beginning and see their results published after the conclusion of the study.
